CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for ...

In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

Objectives The impact of body mass index (BMI) on cardiovascular risk in rheumatoid arthritis (RA) is unclear. RA characteristics may influence the association between BMI and risk. Disease activity, ...

The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, the Centers for Medicare and Medicaid Services said in a filing published ...

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the federal ...

Expanding obesity treatment access could generate $10 trillion for the country by boosting productivity, cutting healthcare ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal ...

Health and Human Services Secretary Robert F. Kennedy Jr. has been critical of the drugs, instead placing a focus on ...

Clin Lipidology. 2014;9(2):179-187. The effects of above mentioned current and novel anti-obesity drugs on lipids are summarized in Table 1.

"Historically, anti-obesity drugs have been plagued by failures, often proving ineffective or unsustainable. However, a new class of medications known as GLP-1 receptor agonists has shown ...